FDA's Final NDI Guidance: What Canadian Ingredient Suppliers and NHP Exporters Must Prove

On 19 October 2026, the United States Food and Drug Administration finalized three long-awaited sections of its guidance on New Dietary Ingredient (NDI) notifications. For Canadian ingredient makers and natural health product companies that sell, or plan to sell, into the United States, this is the clearest statement in years of what an NDI notification must prove about an ingredient's identity and safety. The finalized sections trade vague expectations for concrete recommendations, and they raise the bar on the evidence you need in hand before you file.

If your U.S. buyer sells your ingredient as a dietary supplement, or your Canadian NHP is marketed south of the border as a supplement, an NDI notification may be the single document standing between you and the American market. This article explains what changed, what you must now prove, and where the guidance still leaves questions open.

Executive Summary

The FDA finalized Sections VI.A, VI.B and VI.C of its 2016 revised draft guidance, covering the identity of the ingredient and the finished supplement, history of use or other evidence of safety, and the summary that ties your safety conclusion together. The rest of the 2016 draft stays in draft form. Three shifts matter most for Canadian suppliers:

• Identity is now a defined evidence package. FDA expects composition, physical and chemical characteristics, marker substances, batch-to-batch standardization, impurities, contaminants and validated analytical methods, with category-specific detail for botanicals and live microbials.
• History of use alone needs about 25 years. When you rely on history of use as your main safety argument, FDA generally recommends at least 25 years of widespread use under comparable conditions. Shorter histories can work only with added safety evidence.
• One safety narrative, not a stack of studies. FDA replaced the separate comprehensive safety profile with a single safety narrative that walks the reviewer through your evidence and your conclusion.

What FDA Finalized on 19 October 2026

What is it? The guidance is titled New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI. It finalizes three sections of the FDA's long-running 2016 revised draft: identity information (Section VI.A), history of use or other evidence of safety (Section VI.B), and the summary of the basis for your conclusion of safety (Section VI.C). It appeared in the Federal Register as document 2026-21453 under docket FDA-2025-D-6501.

Why does it matter? An NDI is a dietary ingredient that was not marketed in the United States before 15 October 1994. Under section 413 of the Federal Food, Drug, and Cosmetic Act and 21 CFR 190.6, the manufacturer or distributor must notify FDA at least 75 days before marketing, unless the ingredient qualifies for an exception. For years, suppliers guessed at what a notification needed. These sections put the expectations in writing.

What should companies do? Treat the three finalized sections as your table of contents. Build an identity dossier, decide early whether history of use alone will carry your safety case, and draft a single safety narrative rather than a pile of disconnected reports. These are recommendations, not binding rules, but FDA reviewers will read your notification against them.

How does it affect compliance? A notification that skips the now-expected identity or safety elements is more likely to draw an FDA objection letter, which can stall or stop U.S. marketing. The guidance does not approve ingredients. It is a notification process, so the burden sits with you to make the safety case clearly the first time.

Identity: Proving What Your Ingredient Actually Is

What is it? Identity is the FDA's way of confirming that the ingredient you describe is the same ingredient you will sell, batch after batch. The finalized Section VI.A asks for a structured package rather than a one-line description.

FDA recommends that an identity package cover the elements below. The detail expected scales with the complexity of the ingredient, so a single-molecule compound needs less than a multi-constituent botanical extract.

Botanicals need their botany on the record

For botanical ingredients, FDA wants the scientific nomenclature, the part of the plant used, source and cultivation information, and the processing details, along with controls for potential adulterants and naturally occurring toxins. A Latin binomial and a supplier certificate are not enough on their own.

Live microbials need strain-level identity

For probiotics and other live microbials, FDA expects the Latin binomial name, the strain origin, the methods used to isolate and establish identity, the location of the reference strain, and how it relates to the strains used for your history-of-use or safety evidence. Canadian suppliers who already manage strain identity and viable counts for NHP probiotics will recognize the discipline, but the U.S. documentation expectations are stricter and more explicit.

History of Use: The 25-Year Benchmark

What is it? History of use is the argument that an ingredient is reasonably expected to be safe because people have consumed it safely for a long time under conditions comparable to the ones you propose. Section VI.B sets out how FDA weighs that argument.

Why does it matter? When a notifier relies on history of use alone, FDA generally recommends at least 25 years of widespread use. The use must be by large populations and under conditions, including dose, form, and population, that resemble what you intend to market. A long tradition of use in a different form, at a lower dose, or in a narrow population may not carry the full case.

What should companies do? Map your proposed conditions of use against the documented history. If the history falls short of 25 years, or the conditions do not match, plan to add safety evidence such as genetic toxicity testing, validated in vitro or in silico methods, animal studies or human data. FDA signalled a more flexible, case-by-case approach and removed some long-term animal and reproductive toxicity expectations from the 2016 draft, but flexibility is not the same as a lower bar.

How does it affect compliance? A weak history-of-use case is a common reason FDA objects to a notification. Deciding your evidence route early, before you commit to a filing date, protects your launch timeline.

The Safety Narrative: One Story, Not a Stack of Studies

Section VI.C is where the biggest format change lands. FDA replaced references to a separate comprehensive safety profile with a single safety narrative. The narrative is meant to pull together your identity data, your conditions of use, your history of use and any studies into one connected explanation of why the ingredient is reasonably expected to be safe.

For a quality unit, this is a familiar idea in a new place. A good safety narrative reads like a well-written investigation summary: it states the conclusion, lays out the evidence that supports it, and addresses the gaps honestly rather than hoping the reviewer will not notice them. FDA takes a case-by-case view and does not expect a fixed checklist of safety studies, so the narrative, not a template, carries the argument.

The narrative should also address the intended dose and daily intake, the target population, and any safety signals in the published literature. A narrative that ignores a known concern invites a question that is harder to answer after the fact.

What Is Still Draft, and What That Means for Your Filing

FDA finalized only identity and safety. The sections on when an NDI notification is actually required, and the handling of NDI master files, remain in draft. FDA has said it will keep finalizing other parts as its review continues, and a separate draft on the meaning of dietary substance is expected. Section V, covering notification procedures and timeframes, was finalized separately in 2024.

The practical message: you now have firm expectations for what goes inside the notification, but the threshold questions of whether you need to notify, and how to use a master file, still rest on draft guidance, longstanding regulation and legal judgement. That is exactly the kind of mixed landscape where an early regulatory assessment pays for itself.

NDI Notification vs Canada's NHP Framework: Do Not Assume They Match

What is it? Canada licenses natural health products before sale through a product licence and a site licence. The United States does not pre-approve dietary supplements; instead it runs the NDI notification process for ingredients new to the market. A product that is compliant in Canada is not automatically cleared for the United States.

The two systems also classify ingredients differently. A substance treated as a finished NHP in Canada may be an ingredient subject to an NDI notification in the United States, and the raw material versus finished product distinction that drives your Canadian site licence scope does not control the U.S. analysis. Read the U.S. market on its own terms.

An NDI notification clears the ingredient. It does not clear your manufacturing. Canadian exporters still have to meet U.S. dietary supplement good manufacturing practice, where foreign supplement sites are cited at high rates for specification failures under 21 CFR Part 111. The identity specifications you build for the notification should feed straight into your GMP program.

NDI Notification Readiness Checklist

Use this checklist to test whether your ingredient is ready for an NDI notification under the finalized guidance:

• Confirm the ingredient is an NDI (not marketed in the U.S. before 15 October 1994) and that no notification exception applies.
• Assemble the identity package: composition, physical and chemical characteristics, markers, manufacturing steps, specifications and validated methods.
• For botanicals, document scientific nomenclature, plant part, source, cultivation, processing and adulterant and toxin controls.
• For live microbials, document the Latin binomial, strain origin, isolation and identity methods, and the reference strain location.
• Define impurities, residual solvents, heavy metals, microbial limits and potential contaminants, each with a control and acceptance criterion.
• Decide your safety route: history of use alone (target about 25 years of comparable widespread use) or history plus additional safety evidence.
• Match the documented history of use to your proposed dose, form and population; note any mismatch and how you will cover it.
• Draft one connected safety narrative that states the conclusion, presents the evidence and addresses known safety signals.
• Confirm batch-to-batch standardization so every lot matches the ingredient you notified.
• Align the notification specifications with your 21 CFR Part 111 GMP program so identity controls carry through to production.

Common Mistakes

• Treating a supplier certificate as identity. A certificate of analysis is a data point, not the full identity package FDA now expects. Build the dossier yourself.
• Assuming any long history counts. History of use in a different form, dose or population may not support your proposed conditions, even if it spans decades.
• Filing a stack of disconnected reports. The finalized guidance wants one safety narrative. A pile of studies without a connecting argument makes the reviewer do your work and raises the odds of an objection.
• Confusing Canadian clearance with U.S. clearance. An authorized NHP in Canada does not remove the NDI notification question in the United States.
• Ignoring the parts still in draft. Whether you need to notify at all, and how to use a master file, still turn on draft guidance and regulation. Do not treat the finalized sections as the whole picture.

Frequently Asked Questions

What is a New Dietary Ingredient?

A New Dietary Ingredient is a dietary ingredient that was not marketed as a dietary ingredient in the United States before 15 October 1994. If your ingredient meets that definition and no exception applies, the manufacturer or distributor must submit an NDI notification to FDA at least 75 days before marketing it.

How many years of history of use does an NDI notification need?

When you rely on history of use alone to support safety, FDA generally recommends at least 25 years of widespread use under conditions comparable to the ones you propose. A shorter history can still work if you add other safety evidence, such as toxicology testing or human data.

Is a safety narrative required for an NDI notification?

FDA recommends a single safety narrative that connects your identity data, conditions of use and safety evidence into one explanation of why the ingredient is reasonably expected to be safe. It replaces the separate comprehensive safety profile described in the earlier draft. The guidance is a recommendation, but a notification without a clear safety narrative is far more likely to draw an objection.

Does a Health Canada NHP licence cover me in the United States?

No. Canada and the United States run separate systems. A Canadian product licence does not satisfy the U.S. NDI notification requirement, and the two regimes can classify the same ingredient differently. Plan your U.S. entry as its own project.

What parts of the NDI guidance are still in draft?

FDA finalized identity (VI.A), history of use or other evidence of safety (VI.B) and the summary of the basis for the safety conclusion (VI.C). The sections on when a notification is required and on NDI master files remain in draft, and a separate draft addressing the meaning of dietary substance is expected.

What happens if FDA objects to my notification?

FDA can issue a letter stating that the information in your notification does not provide an adequate basis to conclude the ingredient is reasonably expected to be safe. That does not formally bar marketing, but it is a serious compliance signal and marketing against it carries significant enforcement risk. A complete, well-argued notification is the best way to avoid an objection in the first place.

How MFLRC Can Help

MF License & Regulatory Consultants helps Canadian ingredient suppliers and NHP companies turn a market opportunity in the United States into a defensible NDI notification. We run NDIN gap assessments against the finalized guidance, build identity and specification programs that hold up batch to batch, qualify your suppliers, and draft the safety narrative and supporting dossier. Where your ingredient may instead fit the food pathway, we also advise on GRAS notification, so you choose the right route before you spend on the wrong one.

Our team brings more than 20 years of quality assurance and regulatory affairs experience across pharmaceuticals, natural health products and food. We pair the NDI work with SOP development, gap assessments and the GMP program you will need once the ingredient is cleared, so the specifications you file actually run on your production floor.

Planning to sell a novel ingredient in the United States? Contact MFLRC for an NDIN readiness assessment tailored to your ingredient and market.

Conclusion

The finalized NDI guidance does not change the law, but it ends years of guessing about what a notification must contain. Identity is now a defined evidence package, history of use carries a clear 25-year benchmark when used alone, and the safety case lives in a single narrative. For Canadian suppliers eyeing the United States, the winners will be the companies that build the identity and safety evidence early, treat the U.S. market on its own terms, and file a notification that answers the reviewer's questions before they are asked.

Sources and References

• FDA, Constituent Update: FDA Issues Guidance on Identity and Safety Information for New Dietary Ingredient Notifications (19 October 2026)
• FDA, New Dietary Ingredients (NDI) Notification Process
• eCFR, 21 CFR 190.6, Requirement for premarket notification of a new dietary ingredient
• Health Canada, Natural and non-prescription health products